all-trans-9-<2.2.6-Trimethyl-cyclohexyl>-3.7-dimethyl-nonatetraen-(2.4.6.8)-saeure | 19907-33-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: all-trans-9-<2.2.6-Trimethyl-cyclohexyl>-3.7-dimethyl-nonatetraen-(2.4.6.8)-saeure
• 英文别名: Retinyl ester；(2E,4E,6E,8E)-3,7-dimethyl-9-(2,2,6-trimethylcyclohexyl)nona-2,4,6,8-tetraenoic acid
• CAS: 19907-33-6
• 化学式: C₂₀H₃₀O₂
• 分子量: 302.457
• InChiKey: WWDMJSSVVPXVSV-YCNIQYBTSA-N

物化性质

• 沸点：
  445.2±14.0 °C(Predicted)
• 密度：
  0.982±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-二乙基膦酰基-3-甲基-2-丁烯酸甲酯 、 all-trans-5-(2,2,6-Trimethyl-cyclohexyl)-3-methyl-pentadien-(2,4)-al 生成 all-trans-9-<2.2.6-Trimethyl-cyclohexyl>-3.7-dimethyl-nonatetraen-(2.4.6.8)-saeure
  参考文献：
  名称：

  Dihydroretinoic acids and their derivatives. Synthesis and biological activity

  摘要：

  The syntheses of the ring and four side-chain dihydroretinoic acids and/or their esters, 3-7, are described. The syntheses of several other retinoids containing a substituted aromatic ring are also included. The biological activity of the compounds was evaluated in vivo in a chemically induced mouse skin papilloma test and in vitro in two vitamin A deficient assays. The activity observed for 1a, 1c, and 2a in the former test was partially retained in the dihydro derivatives 4b, 4c, and 6b. Similar results were found in the in vitro assays.

  DOI：

  10.1021/jm00217a011

文献信息

• Insulin-producing cells derived from stem cells
  申请人：Hori Yuichi

  公开号：US20070154981A1

  公开（公告）日：2007-07-05

  The disclosure provides, among other things, insulin-producing cells derived from stem cells, such as human stem cells and neural stem cells. The disclosure discloses a relationship between caudalizing factors and the differentiation of insulin-producing cells.

  该披露提供了从干细胞（如人类干细胞和神经干细胞）衍生出的胰岛素产生细胞，其中包括其他内容。该披露揭示了尾端因子与胰岛素产生细胞分化之间的关系。
• Retinoid receptor compositions and methods
  申请人：THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

  公开号：EP0999271A2

  公开（公告）日：2000-05-10

  The present invention relates to novel receptor polypeptides, which, upon interaction with certain ligands, or activation by certain compounds, modulate transcription of certain genes by binding to cognate response elements associated with promoters of such genes. The novel receptors of the invention modulate transcription in the presence of retinoid compounds. The receptors of the present invention differ significantly from known retinoid acid receptors, in protein primar yseqence and in responsiveness to exposure to various retinoids. The invention provides DNAs encoding the novel receptors, expression vectors for expression of the receptors, cells transformed with such expression vectors, cells co-transformed with such expression vectors and with reporter vectors to monitor modulation of transcription by the receptors, and methods of using such co-transformed cells in screening for compounds which are capable, directly or indirectly, of activating the receptors. The invention also provides nucleic acid probes for identifying DNAs which encode additional retinoid receptors of the same class as the novel receptors disclosed herein.

  本发明涉及新型受体多肽，它们在与某些配体相互作用或被某些化合物激活后，通过与与这些基因启动子相关的同源反应元件结合，调节某些基因的转录。本发明的新型受体可在视黄醇化合物存在的情况下调节转录。本发明的受体与已知的视黄酸受体在蛋白质序列和对各种视黄酸的反应性方面有很大不同。本发明提供了编码新型受体的 DNA、表达受体的表达载体、用这种表达载体转化的细胞、用这种表达载体和报告载体共同转化的细胞以监测受体对转录的调节，以及用这种共同转化的细胞筛选能直接或间接激活受体的化合物的方法。本发明还提供了用于鉴定 DNA 的核酸探针，这些 DNA 编码与本发明公开的新型受体属于同一类的其他视黄醇受体。
• Methods for treatment of adenoid cystic carcinoma
  申请人：THE CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US10668039B2

  公开（公告）日：2020-06-02

  The present invention is directed to compositions and methods for treating Adenoid Cystic Carcinoma (ACC).

  本发明涉及治疗腺样囊性癌（ACC）的组合物和方法。
• Use of retinoic acid and analogs thereof to treat central neural apneas
  申请人：Wisconsin Alumni Research Foundation

  公开号：US11045441B2

  公开（公告）日：2021-06-29

  Described is a method of inhibiting central apnea, central hypopnea or obstructive sleep apnea in a mammal. The method includes the step of administering to a mammal a central apnea inhibitory-effective, central hypopnea inhibitory-effective or obstructive sleep apnea inhibitory-effective amount of a composition comprising at least one retinoid or retinoid or retinoic acid receptor agonist.

  描述了一种抑制哺乳动物中枢性呼吸暂停、中枢性呼吸减弱或阻塞性睡眠呼吸暂停的方法。该方法包括以下步骤：向哺乳动物施用中枢性呼吸暂停抑制有效量、中枢性呼吸暂停抑制有效量或阻塞性睡眠呼吸暂停抑制有效量的组合物，该组合物包含至少一种维甲酸或维甲酸或维甲酸受体激动剂。
• Use of retinoids to treat high blood pressure and other cardiovascular disease
  申请人：——

  公开号：US20030008919A1

  公开（公告）日：2003-01-09

  This invention provides methods of treating a disease in a mammal where the disease is characterized by a symptom ameliorated by inhibition of cellular calcium influx. The methods involve administering to the mammal an effective amount of a retinoid and a pharmacologically acceptable excipient.

  本发明提供了治疗哺乳动物疾病的方法，该疾病的特征是通过抑制细胞钙离子流入而改善症状。这些方法包括向哺乳动物施用有效量的维甲酸和药理学上可接受的赋形剂。